Psoriatic Arthritis News and Research

RSS

Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.

New AI tool can speed up the diagnosis of psoriatic arthritis by up to 4 years

Researchers in Israel have shown that a new machine-learning tool can speed up the diagnosis of psoriatic arthritis (PsA) by up to 4 years, potentially preventing irreversible joint damage and deteriorating function for sufferers.

15 May 2022

NYU Langone joins NIH-sponsored program as leading center to discover new targets for autoimmune, inflammatory diseases

NYU Langone Health is joining a new National Institutes of Health (NIH)-sponsored program called Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) as a leading center to discover new targets for therapy in these diseases.

30 Mar 2022

Updated guideline released for managing antirheumatic drugs in patients undergoing hip or knee replacement

The American College of Rheumatology and the American Association of Hip and Knee Surgeons released a summary of their updated guideline for the Perioperative Management of Antirheumatic Medication in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.

28 Feb 2022

The impact of COVID-19 on people with systemic autoimmune rheumatic diseases

A survey demonstrated that patients with systemic autoimmune rheumatic diseases commonly experience augmented disease severity and disrupted treatment regimens of disease-modifying antirheumatic drugs after acute COVID-19 course.

11 Feb 2022

HSS study provides insight into real-world medication use for treatment of psoriatic arthritis

Despite clear directives outlined in the updated guidelines published by the American College of Rheumatology/National Psoriasis Foundation (ACR/NPF) in 2018, there is limited data regarding medication use in real-world clinical practice and patient medication preferences for the treatment of psoriatic arthritis (PsA).

9 Nov 2021

Study shows significant decreases in infections among people with psoriatic arthritis

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows significant decreases in infections among people with psoriatic arthritis over the years 2012-2017.

2 Nov 2021

Researchers identify mechanism behind insufficient treatment efficacy of psoriasis drugs

Interleukin-12 - a messenger molecule of immune cells - was long considered to trigger the development of psoriasis.

22 Oct 2021

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Real-world data looking at biologic treatment and vaccine hesitancy in psoriasis patients is being presented today at EADV’s 30th Congress.

1 Oct 2021

Immune-mediated inflammatory disease may increase risk of severe COVID-19 outcomes

Researchers in the UK have conducted a large population-based study showing that people with immune-mediated inflammatory diseases (IMIDs) appear to be at an increased risk of serious outcomes from coronavirus disease 2019 (COVID-19).

14 Sep 2021

New clinical trial to test third dose of COVID-19 vaccine for immunocompromised people

A new clinical trial to determine whether a third dose of vaccine will improve the immune response for people who have weakened immune systems is launching in the UK.

24 Aug 2021

Investigational treatment improves survival rate of babies lacking thymus

An investigational treatment pioneered by a Duke Health pediatrician resulted in a one-year survival rate of 77% among children born with a rare condition in which they lack an immune system.

4 Aug 2021

EULAR Patient Research Partners join in new research project to advance treatment of psoriatic arthritis

Eleven Patient Research Partners (PRPs) from three organizations (EULAR, GRAPPA-EU, and EUROPSO) participate in the new research project HIPPOCRATES, ensuring the patients' perspective is preserved and prioritized in all research activities to maximize the project's impact.

2 Jul 2021

Exploring young people’s perspectives on patient-reported outcome measures in inflammatory arthritis

Inflammatory arthritis is the name for a group of diseases that cause joint pain and swelling. This happens because the body's immune system attacks its own tissues and causes inflammation.

23 Jun 2021

Switching to a balanced diet restores gut health and suppresses skin inflammation

The secret to healthier skin and joints may reside in gut microorganisms. A study led by UC Davis Health researchers has found that a diet rich in sugar and fat leads to an imbalance in the gut's microbial culture and may contribute to inflammatory skin diseases such as psoriasis.

22 Jun 2021

Passive smoking and air pollution associated with arthritis risk, poor response to RA treatment

RA is an inflammatory autoimmune disease that causes pain, swelling and stiffness in the joints. It can also cause fatigue, and the underlying inflammation may affect other body systems.

18 Jun 2021

Study explores COVID-19 outcomes in people with RA

Arani Vivekanantham and colleagues investigated the association between RA and the risk of COVID-19 diagnosis, hospitalization with COVID-19,and COVID-19-related death.

18 Jun 2021

Methotrexate users fail to achieve adequate immune response to mRNA COVID-19 vaccines

Up to a third of patients taking methotrexate – a common treatment for immune mediated inflammatory conditions such as rheumatoid arthritis and psoriasis/psoriatic arthritis – failed to achieve an adequate immune response to mRNA COVID-19 vaccines in a small study accepted for publication in the journal Annals of the Rheumatic Diseases.

4 Jun 2021

Psoriatic Arthritis News and Research

Further Reading